Progress in research on the roles of TGR5 receptor in liver diseases

References

• Merlen G, Bidault-Jourdainne V, Kahale N, et al. Hepatoprotective impact of the bile acid receptor TGR5. Liver Int. 2020;40(5):1005–1015.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58(1):155–168.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu H, Ding L, et al. Identification of miR-26a as a target gene of bile acid receptor GPBAR-1/TGR5. PLoS One. 2015;10(6):e0131294.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–9440.
   PubMed Web of Science ®Google Scholar
• Keitel V, Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol. 2012;36(5):412–419.
   PubMed Web of Science ®Google Scholar
• Sawitza I, Kordes C, Götze S, et al. Bile acids induce hepatic differentiation of mesenchymal stem cells. Sci Rep. 2015;5:13320.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006;191(1):197–205.
   PubMed Web of Science ®Google Scholar
• Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol. 2011;25(6):1066–1071.
   PubMedGoogle Scholar
• Donepudi AC, Boehme S, Li F, et al. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology. 2017;65(3):813–827.
   PubMed Web of Science ®Google Scholar
• Klindt C, Reich M, Hellwig B, et al. The G protein-coupled bile acid receptor TGR5 (Gpbar1) modulates endothelin-1 signaling in liver. Cells. 2019;8(11):1467.
   PubMed Web of Science ®Google Scholar
• Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65(3):608–617.
   PubMed Web of Science ®Google Scholar
• Greuter T, Shah VH. Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol. 2016;51(6):511–519.
   PubMed Web of Science ®Google Scholar
• McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int. 2018;12(Suppl 1):11–23.
   PubMed Web of Science ®Google Scholar
• Aydin MM, Akcali KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14–21.
   PubMed Web of Science ®Google Scholar
• Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001;344(6):418–423.
   PubMed Web of Science ®Google Scholar
• Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657–667.
   PubMed Web of Science ®Google Scholar
• Passino MA, Adams RA, Sikorski SL, et al. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science. 2007;315(5820):1853–1856.
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218.
   PubMed Web of Science ®Google Scholar
• Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol. 2007;46(6):1064–1074.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-beta, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147(6):1378–1392.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res. 2010;40(11):1128–1141.
   PubMed Web of Science ®Google Scholar
• Wang X, Gao Y, Li Y, et al. Roseotoxin B alleviates cholestatic liver fibrosis through inhibiting PDGF-B/PDGFR-β pathway in hepatic stellate cells. Cell Death Dis. 2020;11(6):458.
   PubMed Web of Science ®Google Scholar
• Borkham-Kamphorst E, Stoll D, Gressner AM, et al. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun. 2004;321(2):413–423.
   PubMed Web of Science ®Google Scholar
• Hao ZM, Fan XB, Li S, et al. Vaccination with platelet-derived growth factor B kinoids inhibits CCl-induced hepatic fibrosis in mice. J Pharmacol Exp Ther. 2012;342(3):835–842.
   PubMed Web of Science ®Google Scholar
• Wang X, Wu X, Zhang A, et al. Targeting the PDGF-B/PDGFR-β Interface with destruxin A5 to selectively block PDGF-BB/PDGFR-ββ signaling and attenuate liver fibrosis. EBioMedicine. 2016;7:146–156.
   PubMed Web of Science ®Google Scholar
• Schoemaker MH, Rots MG, Beljaars L, et al. PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Mol Pharm. 2008;5(3):399–406.
   PubMed Web of Science ®Google Scholar
• Bai Q, An J, Wu X, et al. HBV promotes the proliferation of hepatic stellate cells via the PDGF-B/PDGFR-β signaling pathway in vitro. Int J Mol Med. 2012;30(6):1443–1450.
   PubMed Web of Science ®Google Scholar
• Ferrell JM, Pathak P, Boehme S, et al. Deficiency of both farnesoid X receptor and Takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology. 2019;70(3):955–970.
   PubMed Web of Science ®Google Scholar
• Kaji k, Yoshiji H, Kitade M, et al. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 2008;22:801–808.
   PubMed Web of Science ®Google Scholar
• Huang S, Ma S, Ning M, et al. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism. 2019;99:45–56.
   PubMed Web of Science ®Google Scholar
• Ding L, Sousa KM, Jin L, et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 2016;64(3):760–773.
   PubMed Web of Science ®Google Scholar
• Ullmer C, Alvarez Sanchez R, Sprecher U, et al. Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release. Br J Pharmacol. 2013;169(3):671–684.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
   PubMed Web of Science ®Google Scholar
• Kaya D, Kaji K, Tsuji Y, et al. TGR5 activation modulates an inhibitory effect on liver fibrosis development mediated by anagliptin in diabetic rats. Cells. 2019;8(10):1153.
   PubMed Web of Science ®Google Scholar
• Lu YF, Wan XL, Xu Y, et al. Repeated oral administration of oleanolic acid produces cholestatic liver injury in mice. Molecules. 2013;18(3):3060–3071.
   PubMed Web of Science ®Google Scholar
• Weiskirchen R. Hepatoprotective and anti-fibrotic agents: it's time to take the next step. Front Pharmacol. 2015;6:303.
   PubMed Web of Science ®Google Scholar
• Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12(11):1143–1152.
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011;54(4):1421–1432.
   PubMed Web of Science ®Google Scholar
• Xiao H, Sun X, Liu R, et al. Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy. Pharmacol Res. 2020;151:104559.
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Du Q, Weymouth ND, et al. Smooth muscle α-actin deficiency leads to decreased liver fibrosis via impaired cytoskeletal signaling in hepatic stellate cells. Am J Pathol. 2019;189(11):2209–2220.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181.
   PubMed Web of Science ®Google Scholar
• Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3(4):e113.
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Ikejima K, Yamagata H, et al. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol. 2011;54(6):1195–1204.
   PubMed Web of Science ®Google Scholar
• Perino A, Pols TW, Nomura M, et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J Clin Invest. 2014;124(12):5424–5436.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Yang YH, Tsuneyama K, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011;53(3):915–925.
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Van Kaer L, et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA. 2000;97(10):5498–5503.
   PubMed Web of Science ®Google Scholar
• Biburger M, Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol. 2005;175(3):1540–1550.
   PubMed Web of Science ®Google Scholar
• Biagioli M, Carino A, Fiorucci C, et al. GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis. Cell Mol Gastroenterol Hepatol. 2019;8(3):447–473.
   PubMed Web of Science ®Google Scholar
• Ito K, Okumura A, Junko ST, et al. Dual agonist of farnesoid X receptor and G protein-coupled receptor TGR5 inhibits hepatitis B virus infection in vitro and in vivo. Hepatology. 2021. DOI:10.1002/hep.31712
   Web of Science ®Google Scholar
• Gao S, Ji XF, Li F, et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 predicts prognosis of acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2015;22(2):112–119.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Pompili S, Vetuschi A, Gaudio E, et al. Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. Nutrition. 2020;75-76:110782.
   PubMed Web of Science ®Google Scholar
• Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43(1):173–181.
   PubMed Web of Science ®Google Scholar
• Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol. 2012;302(2):G225–G235.
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302(8):G762–G772.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang T, Heng C, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother Res. 2019;33(12):3140–3152.
   PubMed Web of Science ®Google Scholar
• Carino A, Cipriani S, Marchiano S, et al. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci Rep. 2017;7(1):13689.
   PubMed Web of Science ®Google Scholar
• Bertholet AM, Kazak L, Chouchani ET, et al. Mitochondrial patch clamp of beige adipocytes reveals UCP1-positive and UCP1-negative cells both exhibiting futile creatine cycling. Cell Metab. 2017;25(4):811–822 e4.
   PubMed Web of Science ®Google Scholar
• Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–183.
   PubMed Web of Science ®Google Scholar
• Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258–267.
   PubMed Web of Science ®Google Scholar
• Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605–613.
   PubMed Web of Science ®Google Scholar
• Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151(3):481–488 e1.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
   PubMed Web of Science ®Google Scholar
• Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51(11):1947–1953.
   PubMed Web of Science ®Google Scholar
• Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–443.
   PubMed Web of Science ®Google Scholar
• Arulanandan A, Ang B, Bettencourt R, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13(8):1513–1520e1.
   PubMed Web of Science ®Google Scholar
• Zeb I, Li D, Budoff MJ, et al. Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2016;67(16):1965–1966.
   PubMed Web of Science ®Google Scholar
• Carino A, Marchiano S, Biagioli M, et al. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. Faseb J. 2019;33(2):2809–2822.
   PubMed Web of Science ®Google Scholar
• Gong Z, Zhou J, Zhao S, et al. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. Oncotarget. 2016;7(51):83951–83963.
   PubMedGoogle Scholar
• Merlen G, Ursic-Bedoya J, Jourdainne V, et al. Bile acids and their receptors during liver regeneration: “Dangerous protectors”. Mol Aspects Med. 2017;56:25–33.
   PubMed Web of Science ®Google Scholar
• Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312(5771):233–236.
   PubMed Web of Science ®Google Scholar
• Bhushan B, Borude P, Edwards G, et al. Role of bile acids in liver injury and regeneration following acetaminophen overdose. Am J Pathol. 2013;183(5):1518–1526.
   PubMed Web of Science ®Google Scholar
• Starkel P, Shindano T, Horsmans Y, et al. Foetal 'flat' bile acids reappear during human liver regeneration after surgery. Eur J Clin Invest. 2009;39(1):58–64.
   PubMed Web of Science ®Google Scholar
• Miura T, Kimura N, Yamada T, et al. Sustained repression and translocation of Ntcp and expression of Mrp4 for cholestasis after rat 90% partial hepatectomy. J Hepatol. 2011;55(2):407–414.
   PubMed Web of Science ®Google Scholar
• Fahrner R, Patsenker E, de Gottardi A, et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation. 2014;97(9):892–900.
   PubMed Web of Science ®Google Scholar
• Pean N, Doignon I, Garcin I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology. 2013;58(4):1451–1460.
   PubMed Web of Science ®Google Scholar
• Spirli C, Nathanson MH, Fiorotto R, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology. 2001;121(1):156–169.
   PubMed Web of Science ®Google Scholar
• Merlen G, Kahale N, Ursic-Bedoya J, et al. TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function. Gut. 2020;69(1):146–157.
   PubMed Web of Science ®Google Scholar
• Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology. 2009;50(3):861–870.
   PubMed Web of Science ®Google Scholar
• Beuers U, Hohenester S, de Buy Wenniger LJ, et al. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52(4):1489–1496.
   PubMed Web of Science ®Google Scholar
• Hov JR, Keitel V, Laerdahl JK, IBSEN Study Group, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010;5(8):e12403.
   PubMed Web of Science ®Google Scholar
• Pradhan-Sundd T, Zhou L, Vats R, et al. Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis. Hepatology. 2018;67(6):2320–2337.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Imasato M, Yamazaki Y, et al. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. Gastroenterology. 2014;147(5):1134–1145 e10.
   PubMed Web of Science ®Google Scholar
• Boyer JL. The hepatobiliary paracellular pathway: a paradigm revisited. Gastroenterology. 2014;147(5):965–968.
   PubMed Web of Science ®Google Scholar
• Sakisaka S, Kawaguchi T, Taniguchi E, et al. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 2001;33(6):1460–1468.
   PubMed Web of Science ®Google Scholar
• Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127(1):261–274.
   PubMed Web of Science ®Google Scholar
• Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology. 2004;127(5):1386–1390.
   PubMed Web of Science ®Google Scholar
• Ebnet K. Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. Physiol Rev. 2017;97(4):1529–1554.
   PubMed Web of Science ®Google Scholar
• Grosse B, Degrouard J, Jaillard D, et al. Build them up and break them down: tight junctions of cell lines expressing typical hepatocyte polarity with a varied repertoire of claudins. Tissue Barriers. 2013;1(4):e25210.
   PubMedGoogle Scholar
• Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43(7):1021–1029.
   PubMed Web of Science ®Google Scholar
• Sun J, Hobert ME, Duan Y, et al. Crosstalk between NF-kappaB and beta-catenin pathways in bacterial-colonized intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2005;289(1):G129–G137.
   PubMed Web of Science ®Google Scholar
• Ke B, Shen XD, Kamo N, et al. β-catenin regulates innate and adaptive immunity in mouse liver ischemia–reperfusion injury. Hepatology. 2013;57(3):1203–1214.
   PubMed Web of Science ®Google Scholar
• Rao J, Yang C, Yang S, et al. Deficiency of TGR5 exacerbates immune-mediated cholestatic hepatic injury by stabilizing the β-catenin destruction complex. Int Immunol. 2020;32(5):321–334.
   PubMed Web of Science ®Google Scholar
• Yue S, Zhu J, Zhang M, et al. The myeloid heat shock transcription factor 1/β-catenin axis regulates NLR family, pyrin domain-containing 3 inflammasome activation in mouse liver ischemia/reperfusion injury. Hepatology. 2016;64(5):1683–1698.
   PubMed Web of Science ®Google Scholar
• Rao J, Qin J, Qian X, et al. Lipopolysaccharide preconditioning protects hepatocytes from ischemia/reperfusion injury (IRI) through inhibiting ATF4–CHOP pathway in mice. PLoS One. 2013;8(6):e65568.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia–reperfusion injury by targeting reactive oxygen species. Transplant Rev (Orlando). 2012;26(2):103–114.
   PubMedGoogle Scholar
• Que X, Debonera F, Xie J, et al. Pattern of ischemia reperfusion injury in a mouse orthotopic liver transplant model. J Surg Res. 2004;116(2):262–268.
   PubMed Web of Science ®Google Scholar
• Rao J, Yue S, Fu Y, et al. ATF6 mediates a pro-inflammatory synergy between ER stress and TLR activation in the pathogenesis of liver ischemia–reperfusion injury. Am J Transplant. 2014;14(7):1552–1561.
   PubMed Web of Science ®Google Scholar
• Rao J, Qian X, Li G, et al. ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responses in mouse liver ischemia/reperfusion injury. Am J Transplant. 2015;15(1):76–87.
   PubMed Web of Science ®Google Scholar
• Kaczorowski DJ, Tsung A, Billiar TR. Innate immune mechanisms in ischemia/reperfusion. Front Biosci (Elite Ed). 2009;1:91–98.
   PubMedGoogle Scholar
• Vilatoba M, Eckstein C, Bilbao G, et al. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery. 2005;138(2):342–351.
   PubMed Web of Science ®Google Scholar
• Liu J, Ren F, Cheng Q, et al. Endoplasmic reticulum stress modulates liver inflammatory immune response in the pathogenesis of liver ischemia and reperfusion injury. Transplantation. 2012;94(3):211–217.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Fan Y, Lu L, et al. Ischemic preconditioning protects hepatocytes from ischemia–reperfusion injury via TGR5-mediated anti-apoptosis. Biochem Biophys Res Commun. 2016;473(4):966–972.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou H, Zhuang L, et al. Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice. Liver Transpl. 2017;23(1):63–74.
   PubMed Web of Science ®Google Scholar
• Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45(3):695–704.
   PubMed Web of Science ®Google Scholar
• Renga B, Bucci M, Cipriani S, et al. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids. Am J Physiol Heart Circ Physiol. 2015;309(1):H114–H126.
   PubMed Web of Science ®Google Scholar
• Renga B, Cipriani S, Carino A, et al. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT/FOXOA1 dependent regulation of H2S generation and endothelin-1. PLoS One. 2015;10(11):e0141082.
   PubMed Web of Science ®Google Scholar
• Keitel V, Stindt J, Haussinger D. Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors. Handb Exp Pharmacol. 2019;256:19–49.
   PubMedGoogle Scholar
• Keitel V, Haussinger D. Role of TGR5 (GPBAR1) in liver disease. Semin Liver Dis. 2018;38(4):333–339.
   PubMed Web of Science ®Google Scholar
• Ho FM, Lin WW, Chen BC, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18(3):391–399.
   PubMed Web of Science ®Google Scholar
• Kida T, Tsubosaka Y, Hori M, et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(7):1663–1669.
   PubMed Web of Science ®Google Scholar
• Guizoni DM, Vettorazzi JF, Carneiro EM, et al. Modulation of endothelium-derived nitric oxide production and activity by taurine and taurine-conjugated bile acids. Nitric Oxide. 2020;94:48–53.
   PubMed Web of Science ®Google Scholar
• Michell BJ, Chen Z, Tiganis T, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001;276:17625–17628.
   PubMed Web of Science ®Google Scholar
• Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut. 2016;65(3):487–501.
   PubMed Web of Science ®Google Scholar
• Masyuk TV, Masyuk AI, Lorenzo Pisarello M, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017;66(4):1197–1218.
   PubMed Web of Science ®Google Scholar
• Masyuk TV, Masyuk AI, LaRusso NF. TGR5 in the cholangiociliopathies. Dig Dis. 2015;33(3):420–425.
   PubMed Web of Science ®Google Scholar
• Cao W, Tian W, Hong J, et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol. 2013;304(4):G322–G327.
   PubMed Web of Science ®Google Scholar
• Casaburi I, Avena P, Lanzino M, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012;11(14):2699–2710.
   PubMed Web of Science ®Google Scholar
• Li AD, Xie XL, Qi W, et al. TGR5 promotes cholangiocarcinoma by interacting with mortalin. Exp Cell Res. 2020;389(2):111855.
   PubMed Web of Science ®Google Scholar
• Khan SA, Davidson BR, Goldin RD, et al.; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–1669.
   PubMed Web of Science ®Google Scholar
• Mittal PK, Moreno CC, Kalb B, et al. Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation. Abdom Imaging. 2015;40(6):1520–1557.
   PubMedGoogle Scholar
• Erice O, Labiano I, Arbelaiz A, et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1335–1344.
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–1447.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–4788.
   PubMed Web of Science ®Google Scholar
• Jones KR, Nabinger SC, Lee S, et al. Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. J Surg Oncol. 2018;118:431–439.
   PubMed Web of Science ®Google Scholar
• Ma Y, Deng F, Li P, et al. The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2018;101:648–655.
   PubMed Web of Science ®Google Scholar
• Gupta P, Sata TN, Ahamad N, et al. Augmenter of liver regeneration enhances cell proliferation through the microRNA-26a/Akt/cyclin D1 pathway in hepatic cells. Hepatol Res. 2019;49(11):1341–1352.
   PubMed Web of Science ®Google Scholar
• Ali O, Darwish HA, Eldeib KM, et al. miR-26a potentially contributes to the regulation of fatty acid and sterol metabolism in vitro human hepG2 cell model of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:8515343.
   PubMed Web of Science ®Google Scholar